| budesonide inhalation suspension / Generic mfg. |
| Completed | 1 | 16 | RoW | Budesonide Inhalation Suspension, Pulmicort Respules®, MAP0010 low dose, MAP0010 intermediate dose, MAP0010 high dose | Allergan, MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan, Q-Pharm Pty Limited | Asthma | 12/05 | 05/06 | | |
2006-004045-42: Randomized, Open-Label, Active Controlled, Two-Period Crossover Study To Evaluate Relative Efficacy And Safety of Investigational Captisol-Enabled Budesonide Inhalation Solution (CBIS) Delivered via eFlow Nebuliser and Conventional Budesonide Inhalation Suspension (Pulmicort Respules) Delivered via LC Plus Jet Nebuliser in Adult Patients with Mild To Moderate Persistent Asthma |
|
|
| Ongoing | 1 | 20 | Europe | Captisol-Enabled Budesonide, Pulmicort Respules, CBIS, Pulmicort Respules, Pulmicort Respules | Verus Pharmaceuticals Inc | Asthma | | | | |
2006-003801-21: A Randomised, Open-Label, Active-Controlled, Two-Period Crossover Study to Evaluate Relative Efficacy and Safety of Investigational Captisol-Enabled® Budesonide Inhalation Solution (CBIS) Delivered via eFlow® Nebuliser and Conventional Budesonide Inhalation Suspension (Pulmicort Respules®) Delivered via LC Plus® Jet Nebuliser in Children with Mild-to-Moderate Persistent Asthma |
|
|
| Ongoing | 1 | 20 | Europe | Captisol-Enabled Budesonide, Pulmicort 250 Repsules, CBIS, Pulmicort 250 Repsules, Pulmicort 250 Repsules | Verus Pharmaceuticals Inc | Asthma | | | | |
NCT02187445: Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial |
|
|
| Completed | 1 | 36 | US | Budesonide inhalation suspension, inhaled corticosteroids | Vanderbilt University, Emory University, Children's National Research Institute | Sickle Cell Disease, Asthma, Acute Chest Syndrome | 12/16 | 02/17 | | |
NCT04032834: A Comparison of VR647 and Conventionally Nebulized Budesonide in Healthy Volunteers and Adult Asthma Subjects |
|
|
| Completed | 1 | 34 | US | VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece, VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask | Vectura Limited | Asthma | 05/17 | 05/17 | | |
NCT03421730: A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma |
|
|
| Completed | 1 | 17 | US | VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer | Vectura Limited | Wheezing, Reactive Airway Disease, Mild Asthma | 03/18 | 03/18 | | |
BLANC, NCT04848662: To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years. |
|
|
| Completed | 1 | 12 | US | BDA MDI (PT027) 160/180 μg, PT027, Pulmicort Respules 0.5 MG/ML Inhalation Suspension | Bond Avillion 2 Development LP | Asthma | 07/21 | 07/21 | | |
| Completed | 1 | 29 | Europe | Budesonide Inhalant Product, Budesonide solution administered by nebulization | Aquilon Pharmaceuticals S.A. | Pharmacokinetics | 12/21 | 02/22 | | |
